常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.62/-2.54
|
|
企業價值
16.23M
|
| 資產負債 |
|
每股賬面淨值
-1.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.88M
|
|
每股收益
0.79
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 02:41 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |

1.33 
